NCT06243159 (JY231、ADs) is a EARLY_PHASE1 clinical trial of JY231 in Autoimmune Diseases, sponsored by Shanxi Bethune Hospital.

Who is sponsoring NCT06243159?

NCT06243159 is sponsored by Shanxi Bethune Hospital.

What drugs are being tested in NCT06243159?

Interventions in NCT06243159: JY231.

What condition does NCT06243159 study?

NCT06243159 studies Autoimmune Diseases.

Is NCT06243159 still recruiting?

NCT06243159 is currently not yet recruiting. Last updated 6 February 2024.

Last reviewed 2024-02-06 · How we verify

NCT06243159: JY231、ADs

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

Not yet recruiting EARLY_PHASE1 Last updated 6 February 2024

What this trial tests

EARLY_PHASE1 trial testing JY231 in Autoimmune Diseases in 20 participants. Not yet recruiting.

Timeline

8 February 2024

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Shanxi Bethune Hospital
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	8 February 2024
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

JY231 — full drug profile →

Conditions studied

Autoimmune Diseases — all drugs for Autoimmune Diseases →

Sponsor

Shanxi Bethune Hospital

Who can join

Adults 18 to 65, any sex, with Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of refractory autoimmune diseases

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted spleen modulation: a novel strategy for next-generation disease immunotherapy.
Dong W, Li Y, Fei Q, Li S, et al · · 2025 · cited 16× · PMID 40225564 · DOI 10.7150/thno.111116
Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.
He L, Sun Y, Ma B, Lang G, et al · · 2026 · PMID 42093990 · DOI 10.3389/fimmu.2026.1772428
<i>In Vivo</i> CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation.
Hao L, Lu J, Xue J. · · 2026 · PMID 42065060 · DOI 10.32604/or.2026.076420

Verify or expand the search:

Other trials of JY231

Trials testing the same drug.

NCT06514768 — JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) · EARLY_PHASE1 · recruiting

Other recruiting trials for Autoimmune Diseases

Currently open trials in the same condition.

NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting

Other Shanxi Bethune Hospital trials

Trials by the same sponsor.

NCT07371533 — Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) · NA · not yet recruiting
NCT07514052 — Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study · recruiting
NCT07239375 — Intraosseous Infusion in Hematologic Critical Patients · recruiting
NCT07265037 — Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management · NA · recruiting
NCT07497165 — Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06243159 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanxi Bethune Hospital
Last refreshed: 6 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06243159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing